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Exclusion rates in randomized controlled
trials of treatments for physical conditions:
a systematic review
Jinzhang He1, Daniel R. Morales2 and Bruce Guthrie3*
Abstract
Background: The generalisability of randomized controlled trials (RCTs) can be uncertain because the impact of
exclusion criteria is rarely quantified. The aim of this study was to systematically review studies examining the
percentage of clinical populations with a physical health condition who would be excluded by RCTs of treatments
for that condition.
Methods: Medline and Embase were searched from inception to Feb 11th 2018. Two reviewers independently
completed screening, full-text review, data extraction and risk-of-bias assessment. The primary outcome was the
percentage of patients in the clinical population who would have been excluded from each examined trial.
Subgroup analyses examined exclusion by population setting, publication date and funding source.
Results: Titles/abstracts (20,754) were screened, and 50 studies were included which reported exclusion rates from
305 trials of treatments in 31 physical conditions. Estimated rates of exclusion from trials varied from 0% to 100%,
and the median exclusion rate was 77.1% of patients (interquartile range 55.5% to 89.0% exclusion). Median
exclusion rates for trials in common chronic conditions were high, including hypertension 83.0%, type 2 diabetes
81.7%, chronic obstructive pulmonary disease 84.3%, and asthma 96.0%. The most commonly applied exclusion
criteria related to age, co-morbidity and co-prescribing, whereas more implicit criteria relating to life expectancy or
functional status were not typically examined. There was no evidence that exclusion varied by the nature of the
clinical population in which exclusion was evaluated or trial funding source. There was no statistically significant
change in exclusion rates in more recent compared with older trials.
Conclusions: The majority of trials of treatments for physical conditions examined excluded the majority of
patients with the condition being treated. Almost a quarter of the trials studied excluded over 90% of patients,
more than half of trials excluded at least three quarters of patients, and four out of five trials excluded at least half
of patients. A limitation is that most studies applied only a subset of eligibility criteria, so exclusion rates are likely
under-estimated. Exclusion from trials of older people and people with co-morbidity and co-prescribing is
increasingly untenable given population aging and increasing multimorbidity.
Trial registration: PROSPERO registration CRD42016042282.
Keywords: Randomized controlled trial [V03.175.250.500.500], External validity, Generalizability, Multimorbidity
[N05.715.350.225.500], Aged [M01.060.116.100], Systematic review [V03.850], Real-world evidence
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Background
Randomized controlled trials (RCTs) are the gold standard
method for evaluating the efficacy of treatments because
well-designed RCTs minimize bias and confounding. They
therefore maximize internal validity, giving confidence
that the results are true for the trial population studied.
However, trial populations are often highly selected, which
may weaken the generalizability of RCT evidence in the
sense of leaving uncertainty that the results apply to every-
one with the condition in clinical practice [1, 2]. Some
exclusions from RCTs are justifiable (e.g., where an indi-
vidual is allergic to a medicine). However, Van Spall et al.
estimated that 84.1% of trials published in high-impact
general medical journals between 1994 and 2006 had
poorly justified patient exclusion criteria [3].
A number of studies have shown that various land-
mark RCTs measuring treatment effects, many of which
underpin guideline recommendations and influence
regulatory decision-making, exclude large proportions of
people with the condition being treated [4, 5]. Older
people, women, and people with co-morbidity or co-
prescribing are noticeably excluded from trials [3, 6, 7].
Although there is some evidence that women and older
people are better represented in newer trials, they re-
main under-represented compared with the wider popu-
lation [7]. These patterns of exclusion do not represent
the realities of current and future clinical practice. Most
people with any chronic condition have co-morbidity,
and multimorbidity is the norm in older people [8, 9].
Therefore, guideline-recommended treatment in routine
practice will often require significant extrapolation from
RCT evidence [10, 11], where strict RCT eligibility cri-
teria lead to trial populations significantly differing from
clinical populations seen in routine practice [12, 13].
The problem that strict RCT eligibility criteria pose
for generalizing from RCT-derived evidence is well
known [14, 15]. However, the extent to which trials
assessing treatment effects across different conditions
exclude patients seen and treated in clinical practice is
uncertain. The aims of this study were to undertake a
systematic review of studies estimating the percentage of
people with a chronic physical condition who would be
excluded by RCTs of treatment for that condition and to
examine how exclusion rates varied for different dis-
eases, for different clinical populations, and over time.
Methods
Search strategy
A systematic review was undertaken searching the Med-
line and Embase databases from inception to 11 Febru-
ary 2018 for all studies comparing the percentage of
people from a ‘clinical’ population with a physical condi-
tion who would have been excluded from one or more
trials of treatment intended for that condition. The
search strategy is detailed in Additional file 1.
Inclusion criteria
We included studies published that explicitly examined
the percentage of people with a chronic physical condi-
tion in a defined clinical population who would have
been eligible for one or more selected RCTs of an indi-
vidual patient treatment for that condition (including
medication, surgery and other non-pharmacological in-
terventions). The clinical populations included were not
restricted in terms of their setting or method of sam-
pling and therefore could be any of unselected patients
seen in clinical practice in primary or specialist care, pa-
tients in clinical or research registries, or research co-
horts identified or recruited in these settings. However,
the appropriateness of the clinical population used to
examine exclusion from a particular trial was examined
as part of risk-of-bias evaluation.
Exclusion criteria
We excluded studies examining eligibility for trials of
mental health conditions, studies that were not pub-
lished in English, studies that did not explicitly report
the percentage of patients eligible for trials or where per-
centages of patients eligible could not be calculated from
the available data (e.g., those comparing recruited with
non-recruited patients without examining exclusion in
an underlying clinical population), and studies examin-
ing eligibility for a hypothetical trial or applying a set of
common exclusion criteria from multiple trials instead
of using actual exclusion criteria from single trials. Since
estimated exclusion rates in very small clinical popula-
tions are likely to be imprecise, we also excluded studies
where eligibility was calculated in a clinical population
that included fewer than 100 patients.
Selection of studies
All titles and abstracts were independently screened by
two reviewers to identify papers for full-text review.
Full-text review and data extraction were carried out in-
dependently by two reviewers on the basis of the pub-
lished protocol [16], and disagreements were resolved by
discussion to reach consensus.
Data extraction and quality assessment
Data extraction was carried out by a minimum of two
reviewers, involving a third reviewer where necessary,
and disagreements were resolved by discussion to reach
consensus. Data extracted for each study included the
condition of interest and a description of comparison
clinical population, including the purpose of the clinical
population dataset (e.g., clinical registry and electronic
health record data), health-care setting and location, the
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date of clinical population recruitment or identification,
clinical population size, and the diagnostic criteria used
to define the clinical population. These data were used
to make an assessment of bias on the overall appropriate-
ness of the clinical population. Extracted data for the
underlying trials examined by each study included the ra-
tionale for the choice of trials examined, the type of inter-
vention or treatment in the trial, the listed trial eligibility
criteria that were applied (or not) to each clinical popula-
tion to estimate exclusion rate, and the trial’s source of
funding (pharmaceutical versus non-pharmaceutical).
The primary outcome extracted was the percentage of
patients in the clinical population who would have been
excluded for each trial examined and the reported 95%
confidence interval (CI) of this percentage (which was
calculated if not reported by the authors).
Risk-of-bias assessment
There is no published risk-of-bias tool to assess the
kinds of studies examined. We therefore developed three
pre-specified risk-of-bias criteria that were independ-
ently assessed by two reviewers, namely:
1) How the reviewed paper selected trials to examine.
We evaluated whether there was a systematic
approach to trial selection (e.g., systematic search of
the literature) or a clearly stated justification for the
choice of trials and whether that justification was
judged to be adequate. Studies were considered to
be at low risk of bias if selection rationale were
clearly stated and judged to be justifiable; otherwise,
they were considered to be at high risk of bias.
2) The appropriateness of each trial–clinical
population pair. The appropriateness of each trial–
clinical population pair was assessed in relation to
how well the clinical population appropriately
represented the population for whom the treatment
evaluated in the trial was intended or suitable. For
example, a primary care population of people with
heart failure is appropriate for a trial of beta-
blockers or angiotensin-converting enzyme inhibi-
tors used as long-term treatment [4], whereas an
emergency department population is appropriate
for a trial of treatment in acute, decompensated
heart failure [17]. Studies were considered to be at
low risk of bias if the clinical population was judged
to be representative of real-world populations for
which the trial treatment was intended or indicated,
at high risk of bias if the clinical population was not
considered to be representative of real-world popu-
lations for which the trial treatment was intended
or indicated, and at unclear risk of bias if insuffi-
cient information was provided for assessment.
3) The choice of trial eligibility criteria to examine. The
choice of trial eligibility criteria assessed in relation
to the stated criteria applied and not applied.
Studies were considered to be at low risk of bias for
the choice of trial eligibility criteria assessed in
relation to the stated criteria if they clearly stated
that all important or common criteria were applied;
otherwise, studies were considered to be at high
risk of bias.
Data synthesis and analysis
Some trials were evaluated in more than one clinical
population. In this situation, the trial–clinical population
pair with the lowest percentage of patients was selected
for analysis in order to obtain the most conservative esti-
mate of the percentage of patients excluded. For the
remaining trial–clinical population pairs, the overall me-
dian, range and interquartile range for the primary out-
come (the estimated percentage of the clinical
population excluded by each trial) were calculated and
repeated for condition groups (cardiovascular condi-
tions, diabetes, respiratory conditions, cancer, rheuma-
toid arthritis (RA), human immunodeficiency virus
(HIV) and other conditions) and for individual condi-
tions. Variation was further examined by using linear re-
gression to model unadjusted and adjusted differences in
the percentage excluded by each trial in relation to
whether the clinical population was recruited from pri-
mary or specialist care, whether the trial examined was
publicly funded or industry-funded, the date of trial pub-
lication (with trials grouped into quartiles of publication
date with equal numbers of trials in each group: 1994–
1999, 2000–2003, 2004–2011 and 2012–2018), and risk-
of-bias assessment (low risk of bias versus high or un-
clear risk of bias).
Results
Study characteristics
The searches identified 21,885 articles with a further 18
identified from other sources, including examination of
references of included studies. Non-duplicate documents
(20,754) were screened, and 222 full-text articles were
examined. Fifty studies that examined trial eligibility in
57 distinct clinical populations were included (Fig. 1).
Twenty of the reference clinical populations examined
were primary care or community samples: seven derived
from electronic clinical datasets, three clinical registries,
five research registries, and five survey-derived popula-
tions. Thirty-seven of the clinical populations examined
were specialist samples: 19 derived from record review
of various kinds, four clinical registries, and 14 research
registries. Characteristics of all 50 included studies and
all 57 reference clinical populations are shown in supple-
mentary table S1. The 50 studies provided data on the
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proportion of the reference clinical population that
would have been excluded by 305 trials. Characteristics
of all the trials examined by these studies are shown in
supplementary tables S2, S3, S4, S5, S6, S7, S8, S9, S10,
S11, S12, S13, S14, S15 and S16. Eighty-one (26.6%) of
the trials examined by the 50 studies were published in
1994–1999, 78 (25.6%) in 2000–2003, 75 (24.6%) in
2004–2011, and 67 (22.0%) in 2012–2018. Seventy-five
(24.6%) trials were publicly funded, 203 (66.6%)
industry-funded, and 27 (8.9%) did not record their
source of funding. Included studies examined trial exclu-
sion in 31 physical conditions (seven cardiovascular,
three diabetes, three respiratory, eight types of cancer,
RA, HIV infection, and eight other conditions) (Table 1),
and there was considerable heterogeneity in the treat-
ments being trialed (supplementary table S2). The trials
examined were most frequently evaluating treatments
for RA (51 trials; 16.7%), chronic obstructive pulmonary
disease (COPD) (51 trials; 16.7%), HIV infection (31 tri-
als; 10.2%), heart failure (25 trials; 8.2%) and hyperten-
sion (22 trials; 7.2%).
Percentage of the clinical population excluded from trials
Across all 305 trials, the median rate of exclusion was
77.1% (range 0–100%) of patients, varying from a me-
dian of 42.0% for HIV trials to a median of 89.4% for
respiratory trials (Table 1, Fig. 2). Only 16 (5.2%) tri-
als excluded less than 25% of patients, whereas 159
(52.1%) excluded at least 75%. At single-condition
level, trials of treatments in atrial fibrillation excluded
the fewest patients (median 34.9%, range 32.3–41.2%)
and trials of treatments in asthma the most (median
96.0%, range 64.0–100%). Notably, exclusion rates for
the most common chronic conditions were high, in-
cluding hypertension 83.0%, lipid-lowering drugs in
primary prevention 85.9%, type 2 diabetes 81.7%,
COPD 84.3% and asthma 96.0%.
Inclusion and exclusion criteria used by studies to
estimate exclusion rates
It was only explicit which eligibility criteria had been
used to determine exclusion rates in the clinical popula-
tion for 174 (57.4%) of trials. The most commonly
Fig. 1 Flow diagram of identification, screening and eligibility assessment
He et al. Trials          (2020) 21:228 Page 4 of 11
reported eligibility criterion used to determine exclusion
rates was disease severity for 142 trials (81.4% of trials
where this was reported), most commonly selecting pa-
tients with more severe or less well-controlled disease.
Co-morbidity was reported as being used to determine
exclusion rates for 119 (68.4%) trials, usually as an exclu-
sion criterion (117 [67.2%] trials) but sometimes as an
inclusion criterion (14 [8.0%] trials, for example, to se-
lect patients at higher risk of cardiovascular disease in
diabetes and atrial fibrillation trials). Age was reported
Table 1 Percentage of the clinical population excluded by condition studied
Number of trials Median percentage excluded (range excluded)a
All conditions 305 77.1 (0.0 to 100.0)
Cardiovascular conditions 81 74.7 (1.6 to 98.8)
Heart failure 25 65.0 (18.8 to 92.0)
Hypertension 22 83.0 (1.6 to 98.8)
Stroke/transient ischemic attack 21 83.6 (33.2 to 98.4)
Atrial fibrillation 4 34.9 (32.3 to 41.2)
Coronary heart disease 4 53.1 (2.8 to 84.5)
Lipid lowering for primary prevention 4 85.9 (69.7 to 89.1)
Secondary prevention of myocardial infarction 1 76.8
Diabetes mellitus 16 88.1 (29.8 to 99.0)
Type 2 diabetes 7 81.7 (49.3 to 96.5)
Diabetic ulcers 7 93.3 (29.8 to 99.0)
Type 1 diabetes 2 91.6 (87.5 to 95.6)
Respiratory conditions 78 89.4 (42.4 to 100.0)
COPD 51 84.3 (42.4 to 100.0)
Asthma 17 96.0 (64.0 to 100.0)
Bronchiectasis 10 80.1 (49.0 to 93.0)
Cancer 24 56.6 (13.6 to 81.2)
Breast cancer 12 56.6 (28.9 to 81.2)
Lung cancer 3 71.4 (65.4 to 71.9)
Renal cancer 3 13.6 (13.6 to 48.5)
Colorectal cancer 2 66.7 (65.7 to 67.6)
Bladder cancer 1 45.3
Stomach cancer 1 41.3
Lymphoma 1 70.4
Prostate cancer 1 57.1
Rheumatoid arthritis 51 84.0 (56.0 to 98.7)
HIV infection 32 42.0 (0.0 to 67.6)
Other conditions 23 58.3 (23.7 to 88.9)
Venous thromboembolism prophylaxis 9 41.5 (23.7 to 78.8)
Venous ulcers 7 83.6 (58.3 to 88.9)
Brain injury 2 40.5 (35.9 to 45.0)
Pressure ulcers 1 34.7
Alzheimer’s disease 1 86.5
Fibromyalgia 1 52.1
Irritable bowel syndrome 1 73.1
Incisional hernia 1 62.5
Abbreviations: COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus
a Where there is only one trial–clinical population comparison, the number reported is the value for that comparison; where there are two, the median reported is
the midpoint value between the two
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as used to determine exclusion rates in the clinical
population for 86 (49.4%) trials, most commonly using
an upper age limit for eligibility and other criteria such
as limited life expectancy and inability to comply with
treatment for 56 (32.2%) trials.
Variation by type of condition
HIV trials excluded the lowest percentage of patients
amongst the different conditions (mean 38.4%, 95% CI
31.4 to 45.5) (Table 2). In unadjusted analysis, there
were statistically significantly higher rates of exclusion
for all other conditions compared with HIV trials, and
cancer trials excluded 15.6% more patients, cardiovas-
cular trials 31.8% more, respiratory trials 36.6% more,
RA trials 44.6% more, and diabetes trials 42.4% more.
When adjusted for all other variables, the results
remained similar with significant differences in the per-
centage of patients excluded in trials of different condi-
tions compared with HIV trials; cancer trials excluded
20.4% (95% CI 8.8 to 48.4) more patients, cardiovascu-
lar trials 34.0% (95% CI 24.0 to 44.0) more, respiratory
trials 43.1% (95% CI 31.9 to 54.4) more, RA trials 43.9%
(95% CI 33.4 to 54.4) more, and diabetes trials 46.8%
(95% CI 31.1 to 62.6).
Variation by funding source, clinical population and trial
publication date
Publicly funded trials excluded a mean of 58.2% of pa-
tients (95% CI 52.3 to 64.1), and industry-funded trials ex-
cluded 15.7% more (95% CI 9.6 to 21.7) in unadjusted
analysis, but there was no statistically significant difference
observed after adjustment (difference −4.7%, 95% CI −11.0
to 1.6). Studies where the clinical population was recruited
in primary care excluded a mean of 72.2% (95% CI 69.0 to
75.5). In unadjusted analysis, studies where the clinical
population was in specialist care excluded 6.2% (95% CI
−11.7 to −0.6) more patients, but there was no statistically
significant difference after adjustment (difference −3.0%,
95% CI −9.0 to 3.0). Trials published during 1994–1999
excluded 71.0% of patients (95% CI 65.6 to 76.5) on aver-
age. This was no different in later time periods in un-
adjusted analysis. Although estimated differences were
larger in adjusted analysis with fewer people excluded
more recently, differences remained non-significant
(2012–2018 difference compared with 1194–1999 −6.5%
(95% CI −13.8 to 0.7, P = 0.08).
Risk of bias
In risk-of-bias assessment, 126 (41.3%) of estimates of trial
exclusion rates were assessed as low risk of bias, 104
Fig. 2 Trials ranked in descending order of the percentage excluded in the clinical population studied
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(34.1%) as high risk, and 75 (24.6%) as unclear. High risk
of bias was driven largely by the clinical population used
in the comparison being judged as less appropriate for the
treatment being trialed (supplementary tables S17 and
S18). Comparisons with a low risk of bias had significantly
lower exclusion rates (Table 2). Low-risk studies excluded
59.9% (95% CI 55.7 to 64.1) of patients on average, and
studies rated high/unclear risk of bias excluded 17.2%
more patients (95% CI 12.2 to 22.2). After adjustment for
other characteristics, studies rated high/unclear risk of
bias excluded 9.2% more patients (95% CI 3.5 to 14.8).
Trials where exclusion rates were estimated in multiple
clinical populations
Thirty-eight trials were examined in two or more clinical
populations (Table 3), and 30 were trials of treatment for
RA. Exclusion rates of nine RA trials were each estimated
in three clinical populations [18], whereas exclusion rates
for the remaining 21 were estimated in two clinical popula-
tions [19]. For the nine trials examined in three clinical
populations, estimated exclusion rates were higher in every
comparison in the Veterans’ Affairs Rheumatoid Arthritis
(VARA) cohort (median 97.4%, range 75.6 to 98.4%) when
compared with the Rheumatoid Arthritis Investigators’ Net-
work (RAIN) database (median 89.6%, range 74.7 to 91.6%)
and the National Register for Biologic Treatment cohort
(median 80.0%, range 56.0 to 92.4%). In the remaining 21
trials, estimated exclusion rates in every comparison were
higher in VARA (median 97.4%, range 72.7 to 99.1%) than
in RAIN (median 89.0%, range 64.9 to 93.5%). Such differ-
ences would be expected given variation in the data col-
lected by different registries and in the clinical population
included (VARA, for example, is made up predominately of
male veterans whereas RAIN is a less selected population of
patients attending rheumatology clinics) [20]. Differences
were more variable and sometimes larger for trials of treat-
ments for the other conditions (atrial fibrillation, heart fail-
ure, acute myocardial infarction and COPD) examined in
more than one clinical population, although there was no
consistent pattern to explain this in relation to risk of bias
or the nature of the clinical population (Table 3).
Discussion
Summary of evidence
This study examined estimated exclusion rates in clinical
populations in 305 trials of treatments for physical
Table 2 Exclusion rates by trial characteristics
Variable (number of trials) Unadjusted coefficient (95% CI)a P value Adjusted coefficient (95% CI)a P value
Condition
HIV infection (n = 32) Reference Reference
Cancer (n = 24) 15.6 (5.0 to 26.2) < 0.001 20.4 (8.8 to 32.0) < 0.001
Cardiovascular (n = 81) 31.8 (23.8 to 39.7) 0.003 34.0 (24.0 to 44.0) < 0.001
Respiratory (n = 78) 36.6 (27.8 to 45.3) < 0.001 43.1 (31.9 to 54.2) < 0.001
Rheumatoid arthritis (n = 51) 44.6 (36.9 to 52.2) < 0.001 43.9 (33.4 to 54.4) < 0.001
Diabetes (n = 16) 42.4 (28.2 to 56.7) < 0.001 46.8 (31.1 to 62.6) < 0.001
Other conditions (n = 23) 19.5 (9.2 to 29.8) < 0.001 25.0 (12.2 to 37.8) < 0.001
Trial funding sourceb
Public (n = 75) Reference Reference
Industry (n = 203) 15.7 (9.6 to 21.7) < 0.001 −4.7 (−11.0 to 1.6) 0.1
Comparison clinical population setting
Primary care (n = 198) Reference Reference
Specialist care (n = 107) −6.2 (−11.7 to −0.6) 0.03 −3.0 (−9.0 to 3.0) 0.3
Year of trial publication
1994–1999 (n = 81) Reference Reference
2000–2003 (n = 78) −4.0 (−11.4 to 3.3) 0.28 −4.7 (−10.8 to 1.4) 0.1
2004–2011 (n = 75) − 1.1 (−8.6 to 6.3) 0.76 − 6.2 (−13.1 to 0.7) 0.08
2012–2018 (n = 71) −0.3 (−7.4 to 7.9) 0.95 −6.5 (−13.8 to 0.7) 0.08
Risk of bias
Low (n = 126) Reference Reference
High/Unclear (n = 179) 17.2 (12.2 to 22.2) < 0.001 9.2 (3.5 to 14.8) 0.002
Abbreviations: CI confidence interval, HIV human immunodeficiency virus
a The coefficients are interpreted as the percentage point difference in exclusion in each category compared with the reference
b Twenty-seven trials did not report funding source
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conditions. Almost a quarter of the trials studied ex-
cluded 90% or more of patients, more than half of trials
excluded more than 75% of patients, and four out of five
trials excluded more than 50% of patients. There was
variation in exclusion depending on the condition stud-
ied, but exclusion rates did not differ between studies
using primary versus specialist care clinical populations
to evaluate exclusion rates or between trials that were
publicly versus industry-funded. There was no strong
evidence that rates of exclusion had changed over time.
A third of studies were at high risk of bias, most com-
monly because the clinical population used was not ap-
propriate for the trial examined, and a further quarter of
studies were at unclear risk of bias. Exclusion rates were
lower for studies at low risk of bias where median exclu-
sion was 60.8%, although two thirds of low risk-of-bias
studies would still have excluded more than 50% and
one third more than 75% of patients.
Strengths and limitations
A strength of the study is the systematic approach to
identify and examine the underlying literature by using a
deliberately broad search strategy to maximize sensitiv-
ity. However, the nature of the literature examined and
the fact that there are no clear reporting criteria for such
studies make it possible that some studies were not
identified. Despite this, estimated exclusion rates in 305
trials in 57 clinical populations were included. A key
Table 3 Consistency of findings when the same trial is examined in more than one clinical population
Condition and trial Clinical population Overall risk of bias Percentage excluded
Median percentage (range
for Aaltonen and Vashisht)
Atrial fibrillation
ARISTOTLE (2011)
Yoon (record review for consenting patients in a single hospital)a High 32.3
Lee (primary care electronic medical record population data) Low 38.7
Fanning (record review within multiple hospitals) High 39.5
Desmaele (clinical registry in a single hospital) High 54.5
Hagg (primary care electronic medical record population data) Low 71.1
Atrial fibrillation
ROCKET-AF (2011)
Yoon (record review for consenting patients in a single hospital)a High 34.5
Lee (primary care electronic medical record population data) Low 52.5
Desmaele (clinical registry in a single hospital) High 60.7
Fanning (record review within multiple hospitals) High 64.2
Atrial fibrillation
RE-LY (2009)
Yoon (record review for consenting patients in a single hospital)a High 35.2
Lee (primary care electronic medical record population data) Low 36.2
Fanning (record review within multiple hospitals) High 47.4
Desmaele (clinical registry in a single hospital) High 52.4
Heart failure
MERIT-HF (2000)
Constantino (record review in a single hospital)a Unclear 48.0
Jost (clinical registry in a single hospital) Low 58.8
Masoudi (National Heart Failure Project registry) High 82.6
Heart failure
RALES (1999)
Masoudi (National Heart Failure Project registry)a High 74.7
Costantino (record review in a single hospital) Unclear 76.0
Acute myocardial infarction
GUSTO (1993)
Krumholz (National Research Registry of Myocardial Infarction)a High 84.5
Krumholz (Cooperative Cardiovascular Project registry) High 90.6
COPD
POET-COPD (2011)
Kruis (seven primary care databases)a High 77.0
Halpin (primary care research database) Low 88.2
COPD
UPLIFT (2009)
Kruis (seven primary care databases)a High 58.0
Halpin (primary care research database) Low 77.5
Rheumatoid Arthritis
9 trialsb
Aaltonen (National Register for Biologic Treatment)a High 80.0 (56.0 to 92.4)
Vashisht (RA Investigators’ Network database research registry) High 89.6 (74.7 to 91.6)
Vashisht (Veterans’ Affairs Rheumatoid Arthritis research registry) Unclear 97.4 (75.6 to 98.4)
Rheumatoid Arthritis
21 trialsb
Vashisht (RA Investigators’ Network database research registry)a Unclear 89.0 (64.9 to 93.5)
Vashisht (Veterans’ Affairs Rheumatoid Arthritis research registry) High 97.4 (72.7 to 99.1)
a Marked trials with most conservative estimate of percentage of patients excluded were analysed
b See supplementary table S14 for individual trial comparisons
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observation is that examined studies were heterogeneous
in a variety of ways. Underlying studies varied in how
they selected trials to compare, in their choice of clinical
population, and in the trial inclusion and exclusion cri-
teria they applied. Some of the observed variation in ex-
clusion rates likely reflects the choices made, but these
were not always explicit in the included studies. This
may be related to the fact that there are no clear criteria
for the conduct of such studies. A further limitation is
that we excluded comparisons with fewer than 100 pa-
tients in order to avoid imprecise estimates for common
conditions (although, in practice, only two studies were
excluded as a result). Finally, most of the underlying
studies applied only a subset of eligibility criteria, most
commonly age, co-morbidity and co-prescribing because
these are easily applied to the data contained in coded
data extracted from electronic health records and clin-
ical or research registries. The implication is that true
exclusion rates are likely even higher than reported here
because of unexamined explicit criteria and because trial
recruitment also involves the application of implicit cri-
teria by researchers (such as the presence of frailty and
whether an individual is perceived to be likely to adhere
to trial procedures).
Comparison with other literature
Exclusion and inclusion criteria are not always clearly re-
ported in trial publications. For example, 56% of 255
cancer RCTs published in leading journals had discrep-
ancies between eligibility criteria listed in protocols and
those listed in the papers reporting results, and 96.7% of
these discrepancies imply that the trial population was
broader than it actually was [21]. Examining RCTs pub-
lished in high-impact journals 1994–2006, Van Spall
et al. found co-morbidity, age and co-prescribing used as
exclusion criteria in the majority of the 283 trials exam-
ined, usually without any explicit justification [3]. A
study of 4341 RCTs published in four high-impact gen-
eral medical journals found that 29% had upper age
limits for inclusion that were rarely explicitly justified.
Although the percentage of trials with upper age limits
declined somewhat between 1998 and 2015, absolute
change over time was small [22], and only 7% of RCTs
published in 2012 were specifically conducted in older
patients [23]. Of 319 ongoing RCTs for 10 common con-
ditions registered with ClinicalTrials.gov in 2014, 79%
excluded patients with common co-morbidities [24].
Studies of trials in individual conditions have similar
findings. Only one of 112 RCTs of secondary prevention
of cardiovascular disease published in 2010–2012 justi-
fied the exclusion criteria applied [25]. Two thirds of
RCTs for type 2 diabetes had upper age limits for inclu-
sion, three quarters excluded a range of co-morbidities,
and only 1.4% of the 440 RCTs examined were
specifically in older adults [26]. However, this literature
does not quantify the impact of inclusion and exclusion
criteria on eligibility as we have done here.
Implications for policy, practice and research
Exclusion of patients from trials matters only if the exclu-
sion criteria are effect modifiers of treatment [27], mean-
ing that the benefits or harms of treatment (or both)
systematically vary in the included versus the excluded.
This review found that trial evidence is typically derived
from narrow populations which are usually selected to
have higher risk of outcomes expected to be improved by
treatment (e.g., by selective inclusion of patients at high
cardiovascular risk) and usually selected to have lower risk
of adverse effects (e.g., by selective exclusion of patients
with co-morbidity, co-prescribing and frailty).
Guideline developers, medicine regulators and clini-
cians therefore all face the problem of having to extrapo-
late RCT findings to excluded clinical populations where
benefits and harms may be plausibly different. Simple
extrapolation requires making assumptions that the ben-
efits and harms of treatment are similar in included and
excluded populations [28]. This is often reasonable but
such assumptions do not always hold true. For example,
trial-derived estimated numbers needed to treat (NNTs)
for the use of angiotensin-converting enzyme inhibitors
over about 3 years to prevent end-stage renal disease
(ESRD) in chronic kidney disease are 9–25. Estimated
NNTs to prevent ESRD in clinical populations are more
than 100 because of lower baseline risk of ESRD and
higher risk of competing mortality than observed in trial
populations [29]. Adverse effects and harms from treat-
ment are also usually higher in people with frailty and
polypharmacy [30] and increase with age. Aspirin used
after a cerebrovascular event in patients over 75 years
old, for example, is associated with a fivefold increase in
fatal bleeding compared with younger patients [31]. So
even if treatment benefits are similar in trial and clinical
populations, overall net benefit may still vary.
Careful attention to internal validity has improved the
quality of trial evidence and its systematic synthesis, but
generalizability and applicability are usually less expli-
citly considered [32]. Despite recommendations that sys-
tematic reviews should always discuss applicability of
evidence [33], only a minority actually do [34]. There re-
mains a clear place for efficacy trials in highly selected
populations, but choosing to design such a trial is also
effectively a declaration that the trialists have concerns
that net benefit may be different in excluded popula-
tions. While more restrictive eligibility criteria for early-
stage clinical trials may be appropriate when little is
known about a treatment’s safety and efficacy, enrolment
of more diverse populations for later studies (or adaptive
enrolment to include broader populations depending on
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initial efficacy findings) will help ensure a better under-
standing of the treatment’s effect for all patients likely to
benefit. In this regard, the US Food and Drug Adminis-
tration is exploring recommendations around moderniz-
ing eligibility criteria for cancer clinical trials [35].
Furthermore, robust methods aimed at generating real-
world evidence may help augment evidence from trials.
To facilitate judgements about applicability by clini-
cians, systematic reviewers, guideline developers and
medicine regulators, journals and registries should re-
quire trialists to explicitly report and justify inclusion
and exclusion criteria, should report data on who was
excluded at screening (although much exclusion hap-
pens before formal eligibility screening), and ideally
should report how the trial population compares with
the clinical population from which it was recruited. Age,
co-morbidity and co-prescribing exclusions in particular
require justification, not least because aging populations
mean that for most conditions older people with multi-
morbidity and polypharmacy will be an increasing per-
centage of the clinically treated population [8, 36].
Assessment of the applicability of evidence should be
explicitly reported by systematic reviews and in guideline
development. Extrapolation of evidence is inevitable but
should be explicitly justified when recommendations are
made for all patients with a condition based on trial evi-
dence from narrow subsets of the clinical population. Al-
ternatively, guideline developers may consider making
more nuanced or stratified recommendations that account
for differences between trial and clinical populations [28,
37]. Guideline development therefore needs to be more
informed by evidence about applicability by making
greater use of epidemiological data describing how the
clinical population differs from trial populations. This is
also relevant for medicine regulation, where a better un-
derstanding of differences between trial and real-world
populations may help in risk-minimization planning, in-
cluding in the design of post-authorization safety studies.
Finally, although this review found a large volume of
evidence about exclusion, the quality of that evidence
was variable. Future studies in this field should clearly
justify their selection of trials to examine and prioritize
landmark trials or those cited in high-quality guidelines
since these most clearly define standards of practice.
The clinical population used to examine eligibility
should be clearly described, and its appropriateness for
measuring exclusion rates in the trial being examined
justified. Studies of exclusion should report all eligibility
criteria applied and all criteria not applied and discuss
the implications of this for interpreting the findings.
Conclusions
Most people with any of the physical conditions studied
would be excluded from most trials of treatments for
that condition. This is most commonly because the trial
excludes older people and those with significant co-
morbidity or co-prescribing. Population aging, increas-
ing multimorbidity and increasing polypharmacy make
it imperative that evidence of treatment effectiveness
better match the people whom we actually treat in
clinical practice.
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